Healthcare / biopharmaceutical clients
Revenue Exposure
R&D budgets, outsourcing trends, and healthcare reform at biopharmaceutical clients drive demand for IQVIA's services.
Relevance 95·Dependency 92·Confidence 92
Source evidence
“Outsourcing trends in the biopharmaceutical industry and changes in aggregate spending and research and development budgets could adversely affect our operating results and growth rate.”
Life sciences companies (biopharma, biotech, medical device)
Customer Exposure
Revenue depends on biotech, medical device and pharmaceutical companies as principal clients across R&D and commercialization value chain.
Relevance 95·Dependency 85·Confidence 94
Source evidence
“Our insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders”
Global biopharmaceutical companies
Customer Exposure
Broader partnering arrangements with global biopharmaceutical companies amplify the impact of multi-contract loss or delay.
Relevance 92·Dependency 90·Confidence 90
Source evidence
“We believe the risk of loss or delay of multiple contracts potentially has greater effect where we are party to broader partnering arrangements with global biopharmaceutical companies.”
Clinical trial regulations (FDA/EMA/MHRA, GLP/GCP, DEA)
Regulatory Exposure
Clinical development services must comply with FDA, EMA, MHRA, GLP/GCP and DEA requirements; non-compliance could bring sanctions, penalties, and liability.
Relevance 90·Dependency 85·Confidence 93
Source evidence
“we must adhere to applicable regulatory requirements such as those required by the FDA, the EMA and the competent authorities of the member states of the EU, and the MHRA in the UK”
Data suppliers (~150,000)
Supplier Dependency
IQVIA's data assets—core to its intelligence offerings—are sourced from approximately 150,000 data suppliers across more than one million data feeds.
Relevance 90·Dependency 75·Confidence 92
Source evidence
“approximately 68 petabytes of unique proprietary data sourced from approximately 150,000 data suppliers and covering over one million data feeds globally”
Third-party data
Supplier Dependency
Commercial Solutions offerings are derived from third-party data; supplier restrictions or refusals could impair services and results.
Relevance 85·Dependency 85·Confidence 90
Source evidence
“Our Commercial Solutions information services are derived from data we collect from third parties.”
Artificial Intelligence
Demand Driver
Healthcare-grade AI powers IQVIA's offerings and increases clinical trial efficiency from trial design to data submission; subject to emerging AI regulation.
Relevance 85·Dependency 70·Confidence 90
Source evidence
“AI can be used to generate new insights and recommendations, helping to increase clinical trials efficiency at all stages from trial design to data submission.”
Healthcare-grade AI®
Technology Dependency
IQVIA's portfolio is powered by Healthcare-grade AI® trained on its proprietary health data, a key differentiator in clinical development and analytics offerings.
Relevance 85·Dependency 70·Confidence 90
Source evidence
“IQVIA Healthcare-grade AI® supports our AI-powered offerings, engineered to meet the level of precision, speed, and trust needed by the industry.”
Biopharmaceutical services industry competition
Competitive Exposure
Highly competitive industry including larger biopharmaceutical services companies and clients' internal departments; failure to adapt to technological change could materially impact the business.
Relevance 80·Dependency 75·Confidence 90
Source evidence
“The biopharmaceutical services industry is highly competitive and our business could be materially impacted if we do not compete effectively or rapidly adapt to technological change.”
Patent cliff and R&D growth
Demand Driver
Major biopharma efforts to replenish patent-cliff revenue losses and higher NME approval rates drive R&D spending and outsourcing demand.
Relevance 80·Dependency 60·Confidence 88
Source evidence
“major biopharmaceutical companies’ efforts to replenish revenues lost from the so-called "patent cliff," increased access to capital by the small and midcap biotechnology industry”
United States dollar
Currency Exposure
~30% of revenues in ~60 non-USD currencies create translation exposure on consolidated USD-reported results
Relevance 78·Dependency 70·Confidence 95
Source evidence
“Because a large portion of our revenues and expenses are denominated in foreign currencies and our financial statements are reported in United States dollars, changes in foreign currency exchange rates can significantly affect our results of operations.”
Clinical trial supplies (drugs, kits, reagents)
Raw Material Dependency
Third-party drugs, kits, reagents and maintenance providers are critical support services whose failure would materially harm the business.
Relevance 75·Dependency 78·Confidence 88
Source evidence
“The failure of any of these third parties to adequately provide the critical support services could have a material adverse effect on our business.”
AI (Healthcare-grade AI)
Revenue Exposure
Portfolio solutions powered by Connected Intelligence and Healthcare-grade AI; commitment to responsible AI with privacy, regulatory compliance and patient safety
Relevance 75·Dependency 60·Confidence 90
Source evidence
“IQVIA's portfolio of solutions are powered by IQVIA Connected Intelligence™ to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI®, advanced analytics”
Skilled labor competition
Cost Driver
Competition for AI/ML, clinical, and technical talent, inflation, and immigration restrictions could raise wage costs and impair hiring/retention.
Relevance 72·Dependency 70·Confidence 88
Source evidence
“Increases in inflation, competition and shortages of qualified personnel in certain specialty areas may make it more difficult to hire and retain our key employees and could result in substantial increased costs, such as increased wage rates”
Health data and analytics technology
Technology Dependency
Technology & Analytics Solutions provides mission critical information, technology solutions and real world insights; data acquisition/processing is a cost component
Relevance 72·Dependency 65·Confidence 85
Source evidence
“Technology & Analytics Solutions provides mission critical information, technology solutions and real world insights and services to our life science clients.”
Payments to clinical trial investigators
Cost Driver
Reimbursed expenses comprised principally of investigator payments and travel are a principal cost component
Relevance 70·Dependency 65·Confidence 90
Source evidence
“Reimbursed expenses, which are included in cost of revenues, are comprised principally of payments to investigators who oversee clinical trials and travel expenses for our clinical monitors and sales representatives.”
Credit and capital market conditions
Revenue Exposure
Client financing difficulties have caused cancellations, scope changes, and late payments in R&D Solutions; credit disruptions also affect interest expense on floating-rate-type debt.
Relevance 68·Dependency 62·Confidence 85
Source evidence
“cancellations, changes in scope and failure to pay timely were attributable, at least in part, to difficulty in our clients' ability to obtain financing”
Emerging markets life sciences growth
Demand Driver
Emerging market pharmaceutical spending expected to grow at 5-8% CAGR through 2030, driving demand for localized data and clinical development capabilities.
Relevance 65·Dependency 45·Confidence 87
Source evidence
“spending on pharmaceuticals in emerging markets will expand at a 5% to 8% compound annual growth rate (“CAGR”) through 2030”
Interest rates / debt balances
Cost Driver
Interest expense rose to $729M in 2025 on higher debt balances; interest income fell on lower deposit rates
Relevance 62·Dependency 60·Confidence 90
Source evidence
“Interest expense during 2025 increased compared to 2024 as a result of higher outstanding debt balances.”
Workforce/restructuring overcapacity
Cost Driver
Restructuring to reduce overcapacity and consolidate functions continuing through 2026
Relevance 60·Dependency 55·Confidence 85
Source evidence
“ongoing efforts to streamline our global operations and reduce overcapacity to adapt to changing market conditions and integrate acquisitions”
EU AI Act
Regulatory Exposure
IQVIA's AI-powered offerings must comply with the EU AI Act and Colorado AI Act, with policies for higher-risk and lower-risk AI activities.
Relevance 60·Dependency 40·Confidence 93
Source evidence
“supports our compliance with existing laws ... and emerging AI regulation such as the European Union’s Artificial Intelligence Act (the "EU AI Act") and the Colorado AI Act.”
Healthcare regulatory compliance
Cost Driver
Rising compliance costs at clients push outsourcing demand, while IQVIA itself bears compliance costs across privacy, laboratory and clinical regulations.
Relevance 60·Dependency 40·Confidence 85
Source evidence
“Despite expected accelerating growth in the global life sciences market, we believe our clients will face increased operating margin pressure due to their changing product mix, pricing and reimbursement challenges, and rising costs of compliance.”